KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) Cost of Revenue (2016 - 2026)

Pacific Biosciences Of California has reported Cost of Revenue over the past 15 years, most recently at $28.1 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 3.73% year-over-year to $28.1 million; the TTM value through Dec 2025 reached $114.2 million, down 2.15%, while the annual FY2025 figure was $114.2 million, 2.15% down from the prior year.
  • Cost of Revenue for Q4 2025 was $28.1 million at Pacific Biosciences Of California, up from $22.5 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $48.8 million in Q4 2023 and troughed at $13.2 million in Q2 2021.
  • A 5-year average of $27.2 million and a median of $28.1 million in 2025 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: surged 119.63% in 2023 and later tumbled 40.22% in 2024.
  • Year by year, Cost of Revenue stood at $30.2 million in 2021, then dropped by 26.46% to $22.2 million in 2022, then soared by 119.63% to $48.8 million in 2023, then tumbled by 40.22% to $29.2 million in 2024, then fell by 3.73% to $28.1 million in 2025.
  • Business Quant data shows Cost of Revenue for PACB at $28.1 million in Q4 2025, $22.5 million in Q3 2025, and $25.1 million in Q2 2025.